Regeneus receives R&D tax incentive refund of $2.4m
Filed with ASX · · 1 page · English
Earlier from Cambium Bio
- Positive clinical trial results for cancer vaccine
- US Patent Office to allow key patent for Progenza
- Update on licensing Progenza in Japan
- European Medicines Agency grants Progenza ATMP status
- Japanese Patent Office to grant patent for cancer vaccine
Later from Cambium Bio
- Progenza patent to grant in Europe
- Re-Released - Appendix 4C - Quarterly
- Chinese patent granted for biomarkers for stem cell therapy
- New CEO Appointed to Accelerate Global Growth
- Response to ASX Appendix 4C Query Letter
Follow Cambium Bio into a list and get an email when it puts out news.
Follow Cambium Bio